Introducing Subcutaneous Nivolumab: Opdivo Qvantig

Oncology infusions can be time-intensive for patients and care teams, but newer subcutaneous therapies like nivolumab and hyaluronidase-nvhy offer faster, more efficient options.

Join Misty Simpson, PharmD from Bristol Myers Squibb, for an in depth discussion on nivolumab and hyaluronidase-nvhy, a subcutaneous alternative to infusion therapies that offers a 3-5 minute administration time. Gain insight into its FDA approval, efficacy, dosing, safety, and potential adverse effects.